Back to search results

Study of LY4515100 for Pain After Wisdom Tooth Removal

This study is looking at a new medication called LY4515100 to see how well it reduces pain after having your wisdom teeth (third molars) removed. Researchers want to compare LY4515100 to a placebo (a pill with no active medicine) to understand its safety and effectiveness. You might be able to join if you are between 18 and 40 years old, have a body mass index (BMI) between 18.5 and 35.0, and need at least two wisdom teeth removed, including two lower ones that are partially or fully impacted. The main goal is to measure how much your pain changes from before treatment up to one day after. The current status of this study is unclear.

Study design
This is an interventional study with a planned enrollment of 212 participants, comparing LY4515100 to a placebo.
What's involved
The study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after your wisdom teeth are removed.
Compensation
Not stated in the trial record.
Follow-up
Pain intensity will be measured from before treatment up to one day after.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07511816

A Study of LY4515100 in Participants With Pain Following Third Molar Removal

Recruiting
PHASE2Ages 18–40InterventionalTreatment
Eli Lilly and Company
~212 participants
Updated 2026-05-01 on ClinicalTrials.gov
What's tested:LY4515100Placebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from Baseline in Self-Reported Pain Intensity
Measured over Baseline, Up to Day 1

Conditions

Acute Pain
Molar
Molar, Third
Surgery, Oral

Explore related trials

Acute Pain

Where it's being run

1 sites across 1 states
Utah1

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
1-317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant has a body mass index (BMI) between 18.5 and 35.0 kilograms per meter squared (kg/m²) inclusive.
Participant requires extraction of 2 or more third molars, including 2 mandibular molars with partial or full bony impaction, confirmed by panoramic X-ray.

Exclusion

Prior dental surgery within 60 days before screening or history of other surgical procedures that could confound surgery or postoperative procedures.
Diagnosis of chronic pain conditions that could confound postsurgical pain reporting in the opinion of the investigator.
Positive urine drug screen or alcohol test during screening or on the day of surgery.
Evidence or history of any other clinically significant hematological, renal, hepatic, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, or neurologic diseases, in the opinion of the investigator, within the last 5 years.
History of malignancy of any organ system treated or untreated, within 5 years prior to consent. The only exceptions are previous in situ carcinoma of the cervix, localized basal cell carcinoma of the skin, or localized squamous carcinoma of the skin if the participant has been treated and is considered cured.

What this trial measures

  • Change from Baseline in Self-Reported Pain IntensityBaseline, Up to Day 1